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Aggressive induction chemotherapy followed by autologous haematopoietic stem cell 
transplant (auto-HCT) is effective for younger patients with mantle cell lymphoma (MCL). 
However, the optimal induction regimen is widely debated. The Southwesterm Oncology 
Group S1106 trial was designed to assess rituximab plushyperCVAD/MTX/ARAC 
(hyperfractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone, 
alternating with high dose cytarabine and methotrexate) (RH) versus rituximab plus 
bendamustine (RB) in a randomized phase II trial to select a pre-transplant induction 
regimen for future development. Patients had previously untreated stage III, IV, or bulky 
stage II MCL and received either 4 cycles of RH or 6 cycles of RB, followed by auto-
HCT. Fifty-three of a planned 160 patients were accrued; an unacceptably high 
mobilization failure rate (29%) on the RH arm prompted premature study closure. The 
estimated 2-year progression-free survival (PFS) was 81% vs. 82% and overall survival 
(OS) was 87% vs. 88% for RB and RH, respectively. RH is not an ideal platform for 
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future multi-centre transplant trials in MCL. RB achieved a 2-year PFS of 81% and a 
78% MRD negative rate. Premature closure of the study limited the sample size and the 
precision of PFS estimates and MRD rates. However, RB can achieve a deep remission 
and could be a platform for future trials in MCL.  
Keywords: 
mantle cell, bendamustine, Auto-HCT, MRD, hyperCVAD 
 
Introduc tion  
Mantle cell lymphoma (MCL) is an aggressive B cell non-Hodgkin lymphoma that 
is considered incurable with conventional therapy. It represents about 4% of lymphomas 
in the US (The Non Hodgkin's Lymphoma Classification Project 1997). For younger 
patients who are fit, the therapeutic strategy has been to use aggressive induction 
chemotherapy followed by autologous haematopoietic stem cell transplantation (Auto-
HCT). The benefit of consolidative Auto-HCT was demonstrated by the European MCL 
network in a trial that compared consolidative Auto-HCT to maintenance interferon and 
showed improved progression-free survival (PFS) in the Auto-HCT arm (median of 39 
months versus 17 months [P = 0.0108])(Dreyling, et al 2005). Although there are a 
variety of upfront regimens, the optimal induction chemotherapy has not been defined. 
The goal of induction chemotherapy has been to achieve a high rate of complete 
response (CR) while minimizing toxicities.  
The R-hyperCVAD (RH) regimen pioneered at MD Anderson Cancer Center 
contains rituximab with hyperfractionated cyclophosphamide, vincristine, doxorubicin and 
dexamethasone, alternating with high dose cytarabine and methotrexate for 6-8 cycles. 
It yields a high CR rate of 87% and overall response rate (ORR) of 97% in single 
institution settings (Romaguera, et al 2005). It has also been tested in the multicentre 
cooperative group setting by the Southwesterm Oncology Group  (SWOG) S0213 trial in 
patients with previously untreated MCL, resulting in a CR of 55%, ORR of 86% and 3 
year PFS of 66% (Bernstein, et al 2013). Single centre studies have demonstrated the 
feasibility of Auto-HCT after abbreviated courses of RH (Till, et al 2008).   
Rummel et al (2005) studied the combination of rituximab plus bendamustine 
(RB) in patients with untreated MCL and showed an ORR of 75% and CR of 50%, with 
minor haematological toxicities. This regimen was then compared to RCHOP (rituximab, 
cyclophosphamide, doxorubicin, vincristine, prednisolone) in a large randomized non-
inferiority trial in Europe, which showed similar ORR rates (93% vs. 91%) and CR rates 
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(40% vs. 30%) to RCHOP but improved median PFS rates (35 months vs. 22 months), 
fewer haematological toxicities (30% vs. 68%), and fewer infections (37% vs. 
50%)(Rummel, et al 2013). These results were confirmed by the BRIGHT study, which 
showed that RB is non-inferior to RCHOP in terms of CR and had less neutropenia 
(Flinn, et al 2014). However, those trials did not include patients consolidated with Auto-
HCT.   
S1106 was designed to assess RH and RB to select an induction regimen 
followed by Auto-HCT consolidation as a platform for development in future trials. The 
hypothesis was that either RH or RB would yield a higher 2-year PFS rate, have fewer 
toxicities, and allow sufficient stem cell mobilization for Auto-HCT consolidation. Besides 
using radiographic imaging to assess for response, we can further characterize response 
status by the use of minimal residual disease (MRD) monitoring. Deep remission as 
defined by MRD status post-induction appears to be a powerful predictor of outcome in 
both single arm (Liu et al 2012) and randomized settings (Pott et al 2010). In this study, 
we use next generation sequencing (NGS) to evaluate MRD status as an important 
biological correlative.   
Me thods  
Patients  
Patients in this study (#NCT01412879) were required to have untreated stage III, 
IV, or bulky stage II MCL. Cyclin D1 (CCND1) positivity was confirmed by 
immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH), and all 
pathological material underwent central histological review through SWOG. Other 
inclusion criteria were age ≥ 18 ≤ 65 years, adequate organ function, no prior treatment 
for MCL, bidimensionally measurable disease >1.5 cm by computed tomography (CT), 
fluorodeoxyglucose (FDG)-avid disease by positron emission tomography (PET), and a 
Zubrod performance status score of 0 - 2.   
Study Design and Treatment 
This randomized phase II study was conducted by SWOG through the National 
Clinical Trials Network (NCTN) adult groups (SWOG/ECOG-ACRIN/Alliance) 
mechanism. Patients were recruited from January 4, 2012 through June 21, 2013. The 
study was approved by the Institutional Review Board at each study site, and written 
informed consent was obtained from all patients prior to any study-specific procedures, 
per the Declaration of Helsinki. The study was approved and sponsored by the Cancer 
Therapy Evaluation Program (CTEP). Patients were randomized to 4 cycles of RH or 6 
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cycles of RB (Fig 1). Randomization was stratified on the MCL International Prognostic 
Index (MIPI) score (Hoster, et al 2008). The dose of RH and RB were previously 
described (Bernstein et al 2013; Rummel et al 2005)(Table I). Only patients achieving 
CR or PR at restaging were eligible to proceed to Auto-HCT consolidation. Patients in 
the RH arm underwent chemotherapy-based stem cell mobilization after cycle 3 with 
granulocyte colony-stimulating factor(dose/schedule per institutional standard). Patients 
in the RB arm underwent stem cell mobilization after cycle 6 (within 8 weeks of last dose 
of RB) using rituximab (375 mg/m2) plus cyclophosphamide (1.5 mg/m2). Plerixafor or a 
second mobilization attempt was allowed but not required per protocol. After at least 1.5 
x 106
Chopra, et al 
1993
 CD34+ cells were collected, patients underwent a second registration and 
proceeded to the transplant component of planned treatment. For patients between 61 
and 65 years old, each site had to select either CBV (carmustine 
[BCNU]/cyclophosphamide/etoposide) or BEAM 
(BCNU/etoposide/cytarabine/melphalan) as the sole preparative regimen (
, Reece, et al 1994) for that site. For patients aged less than 61 years, the sites had 
to select either CBV, BEAM, or total body irradiation/cyclophosphamide/etoposide 
(Nademanee, et al 1995) as the sole preparative regimen.   
 Minimal residual disease (MRD) was assessed at baseline and post-induction 
from peripheral blood. Genomic tumour DNA was extracted from FPE formalin-fixed 
paraffin-embedded tissue or bone marrow aspirate mononuclear cells. Polymerase chain 
reaction (PCR) amplification of IGH VDJ, IGH DJ, and IGK regions was performed 
followed by next-generation sequencing to determine the tumour clonotype(s) (Adaptive 
Biotechnologies Corp, South San Francisco, CA)(Faham, et al 2012). DNA from 
peripheral blood mononuclear cells (PBMC) and plasma was amplified and sequenced 
to determine lymphoma molecules per million diploid genomes. If either the PBMC or the 
plasma sample yielded lymphoma clones, then the patient was deemed to be MRD 
positive.  
Study Assessments 
Baseline evaluations included documentation of disease-related signs and 
symptoms, a physical examination, bone marrow biopsy and radiographic studies, 
including CT of the neck, chest, abdomen and pelvis, and a PET scan. The best clinical 
response was determined by investigators according to the Revised Response Criteria 
for Malignant Lymphoma (Cheson, et al 2007). In the RH arm, response was assessed 
by CT scan after cycles 2 and 4, and a PET scan was done after cycle 4 but prior to 
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Auto-HCT. In the RB arm, CT scans were specified after cycles 4 and 6, and a PET scan 
was done after cycle 6 but prior to Auto-HCT. After Auto-HCT and after removal from 
study treatment, long-term follow up assessments (including survival and disease status 
information) were performed every 3 months for 1 year, every 6 months for 2 year, then 
annually thereafter until either patient death or 8 years after registration. Patients who 
discontinued study treatment with stable disease or better had CT scans every 6 months 
for 3 years and annually thereafter until disease progression. 
Safety monitoring included the recording of adverse events and physical 
examination findings, vital signs, and routine haematology and serum chemistries. 
Adverse events were graded using the National Cancer Institute’s Common Terminology 
Criteria for Adverse Events, version 4 
(http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-
14_QuickReference_8.5x11.pdf). 
Statistical Analysis 
 The primary objective of this Phase II design was to select a regimen for further 
development, and the primary endpoint is estimated 2-year PFS. Recent SWOG 
experience in this patient population in S0213 (Bernstein, et al 2013) and S0601 (Till, et 
al 2016) suggested a historical 2-year PFS of 68%. In order to proceed with 
development, the observed 2-year PFS on the corresponding arm must be at least 75%. 
Under the original design and sample size, this threshold corresponds not only to a 1-
sided 0.05 level test of the null hypothesis that the true 2-year PFS is 68%, but also 
approximates the outcomes observed with the transplant regimen of the Nordic 
Lymphoma Group (Geisler, et al 2008).  
 Interim analyses of stem cell collection data on both treatment arms was 
conducted by the statistical centre. Either arm would be considered unacceptably toxic if 
the true stem cell collection failure rate exceeded 10%. If, among the first 20 eligible 
patients on either arm, more than 4 (20%) were unable to receive transplant because of 
inadequate stem cell collection, then protocol accrual would be held and consideration 
would be given to modifications or closure of that arm. These analyses correspond to 1-
sided 0.05 level tests of the null hypothesis that the true failure rate is 10% or less.  
 Secondary endpoints included ORR, CR, OS, toxicities and MRD analysis. The 
probability of response or a particular toxicity can be estimated to be within at worst 11% 
(95% confidence interval [CI]) with 80 patients per arm. Any adverse event with at least a 
5% probability would be seen at least once (98% chance). This protocol also assessed 
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the association of MRD status at the end of induction therapy, prior to stem cell 
transplant, with PFS. PFS and OS estimates (with 95% CI) were calculated using 
Kaplan-Meier methods (Kaplan and Meier 1958). To minimize selection bias, a landmark 
analysis at 3 months for RH and at 6 months for RB was used for comparing PFS 
between transplanted and non-transplanted patients. In this analysis, only patients on 
RH with at least 3 months of follow-up without progression or patients on RB with 6 
months of follow-up without progression were included, and the subsequent progression-
free time after 3 months of follow-up for RH and after 6 months of follow-up for RB were 
compared. Four patients on RB who did not receive Auto-HCT were excluded from this 
landmark analysis, as three patients were censored and one patient progressed within 
the 6-months landmark time. The estimated 2-year PFS for patients on RB who achieved 
MRD-negative status at the end of induction was also calculated by Kaplan-Meier 
methods using landmark analysis at time of specimen collected for MRD testing. 
Comparisons of response rate and toxicity rate between treatment arms were performed 
using Fisher’s exact test with two-sided alpha of 0.05. Data as of 10 February  2016 
were included in the analyses. 
 
Results 
Patients 
Patient characteristics are detailed in Table II. This study was closed after 53 
patients were accrued: 18 in RH and 35 in RB arms (RH arm closing first). One patient 
on RH who did not receive any randomized therapy due to the closure of RH arm for 
safety was excluded from all endpoint analyses. The groups were well-balanced (Table 
II) with the exception of more females in the RH group. The median age was 57 (range, 
33-64) years in the RB arm and 58 (range, 44-66) years in the RH arm. Ninety-one per 
cent of the patients in the RB arm and 94% of the patients in the RH arm had stage IV 
disease. Eighty-six per cent of the patients in the RB arm and 82% of the patients in the 
RH arm had bone marrow involvement. Ninety-one per cent of the patients in the RB 
arm and 88% of the patients in the RH arm had extra-nodal disease. Lastly, 37% of the 
patients in the RB arm and 35% of the patients in the RH arm were considered 
intermediate/high risk by MIPI score. Approximately 20% of the patients in each arm 
were considered high risk as determined by a Ki67 score > 30%.   
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Efficacy 
The ORR was 94.1% in the RH arm versus 82.9% in the RB arm (p=0.4). The 
CR rates were 40% and 35% for RB and RH, respectively, and the PR rates were 43% 
and 59% for RB and RH, respectively. One patient in the RH arm and 6 patients in the 
RB arm were not evaluable and considered to be non-responders (did not receive 
radiographic imaging). The median follow-up was 37 months in the RH arm and 33 
months in the RB arm. The estimated 2-year PFS was 81% vs. 82% and estimated 2-
year OS was 87% vs. 88% for RB and RH respectively (Figs 2-3). In the RH arm, 5 
patients received Auto-HCT on protocol, and 4 patients received Auto-HCT off protocol 
(discontinued therapy early for toxicities). The 2-year PFS estimates from the landmark 
at 3 months of follow-up are 75% vs. 88% (p=0.43) for patients that underwent Auto-
HCT versus those who did not. In the RB arm, 21 patients received Auto-HCT on 
protocol, 2 received Auto-HCT off protocol, and 12 patients did not receive Auto-HCT. 
The 2-year PFS estimates from the landmark at 6 months of follow-up for patients who 
did not or did receive Auto-HCT was 60% vs. 81% (p=0.20). 
Safety 
The RH arm had significantly more marrow toxicity compared to the RB arm, with 
increased Grade 3 or 4 thrombocytopenia (71% vs. 17%) (p<0.001), anaemia (59% vs. 
8.6%) (p<0.001), neutropenia (65% vs. 34%) (p=0.07), and febrile neutropenia (29% vs. 
14%) (p=0.26) (Table III). The RB arm also had fewer observed Grade 3 or 4 non-
haematological adverse events, but numbers are too small for a definitive comparison. 
Grade 3 or 4 non-haematological adverse events that occurred in greater than 5% of the 
patients on the RH arm were hypokalaemia (29%), hypophosphataemia (24%), 
hyperglycaemia (12%), aspartate transaminase (AST) elevation (5.9%), alanine 
transaminase (ALT) elevation (5.9%), catheter-related infection (5.9%), dehydration 
(5.9%), diarrhoea (5.9), epistaxis (5.9%), nausea (5.9), rash (5.9%) and syncope (5.9%). 
The sole grade 3 or 4 non-haematological adverse event that occurred in greater than 
5% of patients on the RB arm was hypokalaemia (5.7%).  
Twenty-six patients did not finish the course of induction chemotherapy followed 
by Auto-HCT. On the RH arm, 7/17 patients could not finish induction chemotherapy, 
mostly because of delayed platelet recovery (Table IV). An additional 5 patients could 
not mobilize an adequate number of stem cells after cycle 2 of induction chemotherapy. 
This failure to collect an adequate number of stem cells triggered the early stopping 
rules, and the RH arm was closed. On the RB arm, 8/35 could not finish induction 
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chemotherapy and 6 did not undergo Auto-HCT per protocol (Table IV). However, only 2 
patients could not mobilize an adequate number of stem cells. The detailed reasons for 
stopping therapy early are listed in Table IV. The entire study was halted and closed 
because the RH arm encountered the early stopping rule. A result was a smaller sample 
size of the whole study, which limited the precisions around our PFS estimates.    
MRD analysis 
This study also analysed MRD status post-induction therapy via NGS. Twenty-
seven patients consented to the optional MRD analysis, with 12 paired specimens (pre- 
and post-induction therapy, 2 in RH and 10 in RB). In the RH arm, 2 patients were MRD 
positive at baseline; both became MRD negative at the end of induction. In the RB arm, 
1 patient was MRD negative at baseline, and 9 patients were MRD positive. Seven out of 
nine patients converted to MRD negativity at the end of induction (MRD negative rate of 
78%). Interestingly, the remaining 2 patients that were MRD positive at end of induction 
had discordant MRD results between the PBMC and plasma samples. For both patients, 
MRD analysis of the PBMC sample yielded low positive MRD at the end of induction 
(One patient had a 6570-fold reduction and another patient had 22000-fold reduction in 
the lymphoma clonotype per million diploid genome). However, the MRD analysis of the 
plasma sample yielded an MRD negative result. These two patients remain alive and in 
remission. One patient on RB was MRD negative at baseline and remained MRD 
negative at the end of induction. This patient eventually developed progressive disease. 
 There were 3 additional patients that were missing the baseline MRD analysis 
specimens (not included in the 12 paired samples), but were MRD negative at the end of 
induction. One of the 10 patients who was MRD negative at end of induction died 
approximately 3 months after receiving protocol Auto-HCT, and the rest remain in 
remission, with a 2-year landmark PFS of 90% (95% CI: 47.3%, 98.5%).  
 
Discussion 
In this randomized multicentre phase II prospective trial, we showed that both R-
hyperCVAD (RH) and R-bendamustine (RB) are active induction regimens with high 
overall response rates. While the observed complete remission rates were lower than 
historical controls, this may reflect that functional imaging was not mandatory at the first 
restaging, and several patients stopped the study early for toxicity and thus did not finish 
the induction therapy or undergo the post induction FDG scan (Bernstein, et al 2013, 
Romaguera, et al 2005). There were significant differences in toxicity, with the RH arm 
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displaying significantly more grade 3 and 4 anaemia, neutropenia and 
thrombocytopenia. Furthermore, almost one-third of patients on the RH arm failed to 
mobilize even 1.5 x 106
Till, et al 
2008
 stem cells, prompting protocol-specified early termination of 
accrual to the RH arm. Historically, R-hyperCVAD was developed as an 8-cycle regimen 
without stem cell transplantation consolidation. Single institution studies shortened the 
RH regimen to 4 cycles, followed by Auto-HCT, which appeared feasible (
). However, our prospective multicentre trial clearly shows that abbreviated RH 
followed by Auto-HCT is not a viable induction strategy when stem cell transplantation is 
planned. In contrast, the toxicity profile of the RB arm was similar to prior trials (Rummel 
et al 2005; Rummel et al 2013; Flinn et al 2014) and well tolerated. However, 40% of the 
patients did not proceed to Auto-HCT as expected (6% for mobilization failure, 6% for 
progressive disease, 6% for other reasons, 9% for toxicity and 14% for patient choice or 
insurance denial). Although the total number of 14 appears to be high, the numbers were 
low (1-2) for each individual reason given, with the exception of patient choice. Because 
of the small sample size from early trial closure, the true significance of this data is 
unclear. The most common reason for patients not proceeding to Auto-HCT was patient 
choice. It is unclear as to why patients chose not to proceed with Auto-HCT. One 
possibility could be the transition from induction treatment physician to a different 
transplant physician as many centres have a separate transplantation team. It also may 
simply represent the challenges of conducting a randomized multi-step trial involving 
Auto-HCT in the cooperative group setting. However, given that the ORR rate appears 
similar in both RH and RB arms, but RH has more haematological toxicity and stem cell 
mobilization insufficiency, our study supports RB as a more favourable induction 
backbone than RH for MCL.  
The trial’s primary endpoint was to target a 2-year PFS estimate of 75%. The 2-
year PFS estimates of both RH and RB arms were similar at 82% and 81%, respectively. 
Because the study closed prematurely, the precision around the PFS estimates is 
limited. However, the 2-year PFS estimate of 81% is higher than the planned 75%. The 
2-year OS was also similar in both arms at 87% vs. 88%, suggesting that both induction 
regimens followed by auto-HCT may be similar in terms of efficacy, although the small 
sample sizes limit inference. In the RH arm, 5 patients received Auto-HCT on protocol, 
and 4 patients received Auto-HCT off protocol. The 2-year landmark PFS estimates are 
75% vs. 88% for patients that underwent Auto-HCT versus those who did not, 
suggesting that Auto-HCT may not substantially affect 2-year PFS. However, this 
Au
th
or
 M
an
us
cr
ip
t
 This article is protected by copyright. All rights reserved 
analysis is limited by the small sample size. In the RB arm, 21 patients received Auto-
HCT on protocol, 2 received Auto-HCT off protocol and 12 patients did not receive Auto-
HCT. Although the 2-year landmark PFS estimates were appearing more promising for 
patients who received Auto-HCT (81% vs. 60%) (p=0.20), this difference does not meet 
statistical significance.  
Minimal residual disease (MRD) appears to be a potent predictor of outcome, 
and was included as an optional correlative study. Historically, real-time quantitative 
PCR analysis of rearranged immunoglobulin heavy chain (IGH) genes and multicolour 
flow cytometry have been used for MRD assessment in MCL (Pott 2011). Studies using 
these methods show that MRD negative status post therapy can predict for long term 
remission (Bottcher, et al 2008, Pott, et al 2010). However, these approaches have a 
number of limitations, including low sensitivity, failure of marker identification, and 
requirement of patient-specific strategies, which is more cumbersome. NGSuses locus-
specific primer sets of IGH and IGK regions to amplify and sequence cancer-derived 
clones (Faham, et al 2012). These cancer-derived sequences are then used as targets 
that assess for the presence of MRD in follow-up samples. In our study, we evaluated 
MRD status with NGS technology. Twenty-seven patients consented to MRD testing, 
with 12 paired samples of both pre- and post-induction material (peripheral blood). 
Despite this limited sample size, both RH and RB achieved a relatively high rate of MRD 
negative status. Patients with conversion from MRD positive to MRD negative status 
post-induction had excellent outcomes with a 2-year landmark PFS of 90%; three 
patients did not proceed to Auto-HCT. We also observed discordance between MRD 
results from PBMC and plasma samples. It is unclear whether MRD results from PBMC 
or plasma samples are more sensitive or specific. Two patients were low-level MRD 
positive (low number of molecules) by PMBC and negative by plasma at the end of 
induction. These two patients had a dramatic reduction in their lymphoma clonotype 
molecules (6570-fold for one and 22000-fold for another) and still remain in remission. 
The clinical significance of low level MRD positivity is unknown at this time and will need 
to be evaluated in future studies. Although these provocative findings require 
confirmation in a larger study, our data suggest that NGS-based MRD-negative status is 
feasible after RB and could become a new endpoint for future studies and allow for more 
rapid evaluation of new treatment strategies.   
The Nordic Lymphoma Group introduced the concept of adding cytarabine to the 
induction regimen of MCL. In their single arm prospective study, the addition of 
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cytarabine to induction followed by Auto-HCT resulted in a 6-year OS of 70% and PFS of 
66% (Geisler, et al 2008). Of the 160 patients, 145 (91%) were able to collect stem cells 
and proceed to Auto-HCT. Although this was not a randomized trial, this argues for 
inclusion of cytarabine in the induction regimen. A recent publication from the European 
Mantle Cell Lymphoma Network (Hermine, et al 2016) compared 6 cycles of R-CHOP to 
6 cycles of alternating R-CHOP and R-DHAP (rituximab, dexamethasone, high-dose 
cytarabine ,cisplatin) as induction regimen and suggested that the addition of cytarabine 
to induction chemotherapy improves outcomes post Auto-HCT. This study showed an 
improved 5-year PFS in the cytarabine group (65% vs. 44%). It may appear that the 
result from this study is contradictory to our study, as our conclusion was to avoid RH, a 
cytarabine-containing regimen. However, there are a number of similarities in both 
studies, and the difference lies in the interpretation of the data. For example: 1) the 
confirmed CR rate of R-CHOP/R-DHAP was 38%, which is similar to the confirmed CR 
of RB (40%); 2) the MRD negative rate from R-CHOP/R-DHAP was 79%, which is 
similar to the MRD negative rate from RB (78%); 3) the 2-year PFS and OS from R-
CHOP/R-DHAP appear similar to the 2-year PFS and OS from RB. These findings would 
suggest that, although the addition of cytarabine into the induction therapy is 
advantageous to R-CHOP, it may not be necessary when compared to RB. Finally, the 
stem cell collection failure rate was much higher in the R-CHOP/R-DHAP arm as 
compared to the R-CHOP arm (34% vs. 16%). Although the Nordic Lymphoma Group 
did not have problems with stem cell collection with the inclusion of cytarabine, it 
appears that the inclusion of cytarabine and cisplatin (R-DHAP) contributes to stem cell 
mobilization failure.   
A variety of novel therapies have been tested in recent years for 
relapsed/refractory MCL. Bortezomib, a proteasome inhibitor, has demonstrated an ORR 
of 33% and a CR rate of 8% in this setting (Fisher, et al 2006). Patients treated with the 
immunomodulatory agent lenalidomide were shown in a phase II trial to have an ORR of 
35% and a CR rate of 12% (Zinzani, et al 2013). Ibrutinib, a Bruton tyrosine kinase 
inhibitor (Wang, et al 2013), has shown an ORR of 68% and a CR of 21%. These agents 
are now being incorporated into the induction setting as combination therapies. Early 
results from an induction trial of lenalidomide plus rituximab showed an ORR of 92%, CR 
of 64% and a 2-year PFS of 85% (Ruan, et al 2015). The ORR and PFS were similar to 
those in our study and other induction regimens. However, this was a single arm study 
that excluded patients with high-risk MIPI score (unless there were contraindications to 
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chemotherapy) and required patients to be treated for at least 36 cycles of therapy 
unless there was excess toxicity or progressive disease. These results need to be 
confirmed in a larger randomized trial with longer follow-up time. It is possible that the 
addition of novel therapies into induction regimens could result in greater CR rates, 
higher MRD negative responses post-induction, and longer PFS. Although the current 
standard treatment for younger patients is consolidation in first CR post-induction with 
Auto-HCT, it is possible that inclusion of novel therapies into induction or as 
consolidation may change this standard in the future. The current European Network 
younger trial and future US intergroup trials will attempt to answer this provocative 
question.   
Overall, significant progress has been made in understanding the molecular 
biology of MCL, and that has translated into improved outcome. The median OS of 
patients with MCL has been extended from 2.7 years to 4.8 years from the time period of 
1975–1996 to 1996–2004 (Herrmann, et al 2009). Since then, other trials have further 
shown an improvement in OS. The Nordic group used an induction regimen of R-maxi-
CHOP alternating with cytarabine followed by Auto-HCT, showing a median event-free 
survival (EFS) of 7.4 years and median OS of greater than 10 years (Geisler, et al 2012). 
Many novel agents have been discovered and will certainly extend the median OS even 
further.   
In conclusion, this SWOG-led NCTN trial showed that RH was difficult to 
incorporate in a multicentre setting because of toxicity and inadequate stem cell 
mobilization, and is thus not ideal for future development in this setting. In contrast, RB 
had high response rates, a 78% MRD negativity rate, and was generally well tolerated 
with successful stem cell mobilization. In addition, patients achieving MRD negative 
status after induction had excellent outcomes reflected by a 2-year landmark PFS of 
90%. We recognize that 40% of the patients on the RB arm did not proceed to Auto-HCT 
per protocol and that the sample size was small. Thus, the results of this trial need to be 
confirmed. The current Eastern Cooperative Oncology Group-led NCTN trial (NCT 
01415752) using RB with or without bortezomib, followed by rituximab with or without 
lenalidomide, could support our observation. Upon confirmation, future trials should 
focus on MRD analysis as primary endpoints for induction trials, as well as the role of 
Auto-HCT consolidation therapy in patients who are MRD negative post-induction 
therapy.  
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Table I. Study drugs by dose, days administered, and route. 
Cycle 1 and 3 Dose Days Route 
Rituximab 375 mg/m
2
 1 IV 
Cyclophosphamide 300 mg/m 2-4 
2
 IV 
Doxorubicin 16.6 mg/m
2
 5-7 IV 
Vincristine 1.4 mg/m
2
 (cap 2) 5 and 12 IV  
Dexamethasone 40 mg 2-5, 12-15 IV or PO 
Cycle 2 and 4 Dose Days Route 
Rituximab 375 mg/m
2
 1 IV 
Methotrexate 200 mg/m
2
800 mg/m
 IV over 2 h 
2
 IV over 22 h 
2 IV 
Cytarabine 3 g/m
2
 3-4 IV 
Rituximab 375 mg/m
2
 1 IV 
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Table II. Patient characteristics 
Characteristics RH (N=17)* RB (N=35) P-value 
Age, years 59 (44-66) 57 (33-64) 0.23 
Male/female 9 (53%)/8 (47%) 32 (91%)/3 (9%) 0.003 
Performance status 
  0 
  1 
 
11 (65%) 
6 (35%) 
 
26 (74%) 
9 (26%) 
0.52 
Disease stage 
  III 
  IV 
 
1 (5.9%) 
16 (94.1%) 
 
3 (8.5%) 
32 (91.4%) 
1.00 
Bulky disease 1 (6%) 3 (9%) 1.00 
B symptoms 6 (35%) 10 (29%) 0.75 
Bone marrow involvement 14 (82%) 30 (86%) 1.00 
Extranodal involvement 15 (88%) 32 (91%) 1.00 
Elevated lactate dehydrogenase 5 (29%) 9 (26%) 1.00 
Ki67 (N=46) 
  <10% 
  10-30% 
  >30% 
 
20% 
60% 
20% 
 
10% 
68% 
22% 
0.58 
MIPI score 
  Intermediate/high 
  Low risk 
 
6 (35%) 
11 (65%) 
 
13 (37%) 
22 (63%) 
1.00 
MIPI, mantle cell lymphoma International Prognostic Index; RB, rituximab plus 
bendamustine; RH, R-HyperCVAD (rituximab with hyperfractionated cyclophosphamide, 
vincristine, doxorubicin and dexamethasone, alternating with high dose cytarabine and 
methotrexate) 
*18 patients randomized to RH.  However, 1 patient randomized to RH on the day RH 
arm was closed. That patient did not receive RH and instead received RB as per 
investigator choice. Thus only 17/18 patients were included in analysis.   
Table III. Adverse events 
Grade 3/4 toxicities (induction 
phase) 
RH (N=17) RB (N=35) 
Anaemia 59% 8.6% 
Neutropenia 65% 34% 
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Febrile neutropenia 29% 14% 
Thrombocytopenia 71% 17% 
Hypokalaemia 29% 5.7% 
Hypophosphataemia 24% 2.9% 
Hyperglycaemia 12% 0% 
ALT increased 5.9% 0% 
AST increased 5.9% 0% 
Catheter-related infection 5.9% 2.9% 
Dehydration 5.9% 0% 
Diarrhoea 5.9% 0% 
Epistaxis 5.9% 0% 
Nausea 5.9% 0% 
Rash 5.9% 2.9% 
Syncope 5.9% 0% 
ALT, alanine transaminase; AST, aspartate transaminase; RB, rituximab plus 
bendamustine; RH, R-HyperCVAD (rituximab with hyperfractionated cyclophosphamide, 
vincristine, doxorubicin and dexamethasone, alternating with high dose cytarabine and 
methotrexate)Table IV. Reasons for discontinuations 
Reasons for discontinuing 
treatment/stopping before Auto-HCT 
RH (N=17) 
12/17 
RB (N=35) 
14/35 
Failure to collect stem cells 5 2 
Thrombocytopenia 5  
Patient choice  4 
Progressive disease  2 
Pancytopenia 1  
Neutropenia  1 
Allergy  1 
Seizure  1 
Insurance denial  1 
Others 1 2 
Auto-HCT, autologous haematopoietic stem cell transplantation; RB, rituximab plus 
bendamustine; RH, R-HyperCVAD (rituximab with hyperfractionated cyclophosphamide, 
vincristine, doxorubicin and dexamethasone, alternating with high dose cytarabine and 
methotrexate) 
Figure 1. Study schema.  
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Ara-C = cytarabine; BEAM = carmustine [BCNU]/etoposide/cytarabine/melphalan; CBV 
= carmustine [BCNU], cyclophosphamide, etoposide; Cy, cyclophosphamide; HCVAD = ; 
HyperCVAD (hyperfractionated cyclophosphamide, vincristine, doxorubicin and 
dexamethasone, alternating with high dose cytarabine and methotrexate) MTX, = 
methotrexate; PR = partial response; R = rituximab; TBI = total body irradiation; VP16 = 
etoposide. 
 
Figure 2. Two-year progression-free survival 
HCVAD/MTX/Ara-C = HyperCVAD (hyperfractionated cyclophosphamide, vincristine, 
doxorubicin and dexamethasone, alternating with high dose cytarabine and 
methotrexate); R = rituximab. 
 
Figure 3. Two-year overall survival 
HCVAD/MTX/Ara-C = HyperCVAD (hyperfractionated cyclophosphamide, vincristine, 
doxorubicin and dexamethasone, alternating with high dose cytarabine and 
methotrexate); R = rituximab.  
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